TULIP Extension trial shows #SLE Rx w/ anifrolumab + SOC had less organ damage after 208wks. 354 on ANIF (+SOC) vs 561 on SOC alone = ANIF was 59.9% lower SDI (SLE damage index) (HR 0.40) vs those on SOC alone at wk 208. https://t.co/Ox7efMsAW2 https://t.co/55jZBE2aTW

Optimal Management of Rheumatoid Arthritis Patients and Liver Disease https://t.co/KpdY1MEM1w https://t.co/vETGMJgHf3

Livedoid vasculopathy (LV) is a rare chronic microvascular thrombosis dz w/ hypercoagulability and inflammation. Lit Search found 15 articles, 41 LV pts Rx w/ biologics & JAK inhib. 88% w/ positive responses & pain relief. TNFi were most used, then JAK inhibitors… https://t.co/3ugGdUlYcI https://t.co/0aXRKRi5RA

Korean insurance claims data shows #RA pts have a higher risk of renal cancer (vs gen. population), unrelated to serostatus. The renal CA risk (aHR 1.34;1.04–1.78) was higher in women (aHR 1.57); but RA was not assoc w/ risk of CA of bladder, prostate or testes… https://t.co/owSeqibcPu https://t.co/N3TRQuKZJs

Growing Physician Enthusiasm for AI in Healthcare The AMA has just published the results of a U.S. Physician survey and shown MD attitudes have positively shifted regarding the use of artificial intelligence (AI) in healthcare. https://t.co/7nGn5XsfEI https://t.co/sH3yQtaQue

The Cartel is Coming for Rheumatology At first glance, the pharmaceutical marketplace may not appear like a crime drug ring, but Dr. Feldman of Tulane University described how sinister forces of market manipulation have negatively impacted patient care for years.… https://t.co/nOllJFR9AQ https://t.co/IxyGaysOEe

Japanese study of 781 RA pts (78 dx w/ ILD; most UIP pattern). Mortality higher in RA-ILD (SMR 2.09) vs RA (1.16) vs gen population. Mortality increased w/ ILD (adj HR 2.97), advanced age (1.08/per yr) , and low BMI (3.07) https://t.co/EYKfHotZPr https://t.co/xC6E0OLfFs

Combination biologics in PsA: are we there yet? Combination therapy is well-established in rheumatoid arthritis, but its efficacy in psoriatic arthritis (PsA) remains uncertain. Despite effective treatment options, there is a need for solutions for patients unresponsive to… https://t.co/uqLnxLIktM https://t.co/awwaVPOZTu

February 5, 2025, the FDA granted Fast Track designation to ADI-001, an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed/refractory class III or class IV lupus nephritis, & nd SLE with extrarenal Dz… https://t.co/ywXUTKSoB2 https://t.co/Es0F63MBrk

JAMA Review on Dx & Rx of Monoclonal Gammopathy of Undetermined Significance. MGUS has NO Sxs or organ damage. MGUS & Dz associations (OP, Autoimmune) were likely overestimated; M protein testing should be done if malignancy or MGCS is suspected. Risk of progression to malignancy… https://t.co/Jikc5q3BJL https://t.co/hxhcD4bJ2X

Valentine RNL 2025 Review (2.14.2025) Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025. https://t.co/EDCqmtbkyC https://t.co/2GlrslkgGp

That's not my problem - or is it? Multimorbidity in RA RA can look so easy on the television commercials where patients appear young, healthy, and vibrant on the advertised treatment. https://t.co/4lSVKeRtyx https://t.co/Xa1UGbJigy